SCHEMBL10175208

SCHEMBL10175208

O=C(O)c1ccc2nc(-c3ccc(Cl)cc3)c(CO)n2c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GABRA2 P47869 1/20 0.53
GABRB2 P47870 1/20 0.53
ALDH1A1 P00352 1/20 0.51
SLC2A2 P11168 2/20 0.51
NR1I2 O75469 1/20 0.51
ABCB11 O95342 1/20 0.51
ALB P02768 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
TSPO P30536 1/20 0.51
ADORA1 P30542 1/20 0.51
OPRM1 P35372 1/20 0.51
DRD3 P35462 1/20 0.51
OPRK1 P41145 1/20 0.51
PDE4D Q08499 1/20 0.51
KCNH2 Q12809 1/20 0.51
SLC2A1 P11166 9/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1691484 0.89 SLC2A1 (0.60) GABRA2GABRB2ALDH1A1SLC2A2NR1I2
SCHEMBL1691419 0.88 GABRA2 (0.51) GABRA2GABRB2ALDH1A1SLC2A2NR1I2
SCHEMBL14632080 0.87 AKT1 (0.43) GABRA2GABRB2ALDH1A1ALBOPRK1
SCHEMBL1691161 0.85 SLC2A1 (0.56) GABRA2GABRB2ALDH1A1NR1I2ABCB11
SCHEMBL1691320 0.85 SLC2A1 (0.56) GABRA2GABRB2ALDH1A1SLC2A2NR1I2
SCHEMBL1691342 0.85 SLC2A1 (0.56) GABRA2GABRB2ALDH1A1SLC2A2NR1I2
SCHEMBL1691241 0.85 ALDH1A1 (0.68) GABRA2GABRB2ALDH1A1NR1I2ABCB11
Bromide SCHEMBL1691362 0.84 SLC2A1 (0.56) GABRA2GABRB2ALDH1A1SLC2A2NR1I2
SCHEMBL3498373 0.84 CDH1 (0.50) GABRA2GABRB2ALDH1A1SLC2A2NR1I2
SCHEMBL5348158 0.83 AKT1 (0.60) GABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376490-B1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD (GB) 2013-01-23 EP claimed
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS BIOVITRUM AB (PUBL) (SE) 2015-08-27 US disclosed
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS BIOVITRUM AB (PUBL) (SE) 2015-08-27 US disclosed
US-20140206662-A1 Imidazopyridine Compounds PROXIMAGEN LTD. (GB) 2014-07-24 US disclosed
US-20140206662-A1 Imidazopyridine Compounds PROXIMAGEN LTD. (GB) 2014-07-24 US disclosed
US-20120010188-A1 Imidazopyridine Compounds PROMIMAGEN LTD. (GB) 2012-01-12 US disclosed
US-20120010188-A1 Imidazopyridine Compounds PROMIMAGEN LTD. (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010188-A1 Imidazopyridine Compounds SSB, MIF, IDO1 GABRA2 1737/4885GABRB2 2456/4885ALDH1A1 65/4885
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS SSB, MIF, IDO1 GABRA2 1737/4885GABRB2 2456/4885ALDH1A1 65/4885
US-20140206662-A1 Imidazopyridine Compounds SSB, NFKBIA, TPMT GABRA2 1302/4885GABRB2 1903/4885ALDH1A1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.